# US Gestational Diabetes Market > US Gestational Diabetes Market Research Report By Diagnosis Type (Oral Glucose Tolerance Test, Fasting Blood Sugar Test, Random Blood Sugar Test, Hemoglobin A1c Test), By Treatment Type (Dietary Changes, Insulin Therapy, Oral Medications, Physical Activity), By Risk Factor (Obesity, Family History, Age, Previous Gestational Diabetes) and By Patient Age (Teenagers, Adults, Elderly) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.25% - **2024:** $ 417.9 Million - **2025:** $ 444.02 Million - **2035:** $ 814 Million - **Key Players:** Abbott Laboratories (US), Roche Holding AG (CH), Boehringer Ingelheim (DE), Sanofi (FR), Novo Nordisk (DK), Merck & Co. (US), Johnson & Johnson (US), Bayer AG (DE) **Report ID:** MRFR/Pharma/18397-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-gestational-diabetes-market-19944 --- ## Market Summary ## **US Gestational Diabetes Market Overview** As per MRFR analysis, the US Gestational Diabetes Market Size was estimated at 1.81 (USD Billion) in 2023. The US Gestational Diabetes Market Industry is expected to grow from 1.95(USD Billion) in 2024 to 5.07 (USD Billion) by 2035. The US Gestational Diabetes Market CAGR (growth rate) is expected to be around 9.075% during the forecast period (2025 - 2035). ### **Key US Gestational Diabetes Market Trends Highlighted** The US Gestational Diabetes Market is witnessing several important trends driven by increasing awareness around maternal health. As more women are informed about the potential risks associated with gestational diabetes, there is a growing demand for diagnostics and monitoring solutions. The rise in obesity rates among pregnant women has also been identified as a key market driver, leading to a heightened focus on prenatal care and lifestyle management. Moreover, healthcare policies in the US are increasingly supporting improved access to screenings and treatments, which further drives market growth. Opportunities lie in the development of advanced technologies and digital health solutions, including mobile applications for blood sugar monitoring and telehealth consultations. With the advent of new technologies, healthcare providers can offer more personalized care to their patients, which could improve outcomes for mothers and infants alike. Additionally, there is an emerging market for dietary supplements and educational programs targeting nutrition and lifestyle changes during pregnancy, aiming to prevent gestational diabetes or manage its symptoms effectively. Trends in recent times also indicate a stronger emphasis on interdisciplinary care, where obstetricians, dietitians, and endocrinologists collaborate to provide comprehensive management plans. Increased focus on patient education has sparked a shift toward proactive measures for managing gestational diabetes, ensuring that expecting mothers have access to resources that empower them to take charge of their health. Furthermore, policies promoting healthier food options in schools and communities are gaining traction, which can also indirectly influence gestational diabetes outcomes among future generations, highlighting an ongoing commitment to addressing this important public health concern in the US. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **US Gestational Diabetes Market Drivers** #### **Increasing Prevalence of Obesity Among Pregnant Women** The rise in obesity rates among women of reproductive age is a significant driver of the US [Gestational Diabetes Market](../../../reports/gestational-diabetes-market-4591) Industry. According to the Centers for Disease Control and Prevention (CDC), the obesity prevalence among women of childbearing age in the United States is approximately 38%. This alarming figure indicates not only a direct correlation with the likelihood of developing gestational diabetes but also highlights a broader public health concern. As more women enter pregnancy with obesity, the risk of gestational diabetes increases markedly, necessitating better screening and management solutions. Major health organizations, such as the American Diabetes Association, continue to advocate for higher awareness and intervention strategies in managing gestational diabetes, which directly drives market growth by requiring more innovative treatment options, monitoring devices, and educational resources. #### **Rising Awareness and Screening Initiatives for Gestational Diabetes** The increasing focus on prenatal care and early screening initiatives for gestational diabetes is transforming the landscape of the US Gestational Diabetes Market Industry. The American College of Obstetricians and Gynecologists recommends routine screening for all pregnant women, emphasizing the need for early detection to mitigate risks to both mother and child. Reports indicate that approximately 7-10% of pregnant women are diagnosed with gestational diabetes in the U.S. annually. As awareness spreads through public health campaigns, more women are being screened, leading to higher demand for diagnostic tools and treatment options. This proactive approach reflects a significant market opportunity, encouraging companies to innovate and improve on existing products. #### **Technological Advancements in Monitoring and Treatment** Recent technological advancements in diabetes management tools are another critical driver of the US Gestational Diabetes Market Industry. The adoption of continuous glucose monitoring systems has surged, providing expectant mothers with real-time data on glucose levels, thus improving management of gestational diabetes. According to the Food and Drug Administration (FDA), there has been a substantial rise in the number of approved devices reflecting innovation in this sphere. Enhanced features such as mobile applications that track blood sugar levels also play a pivotal role in facilitating better self-management among expectant mothers. These developments not only improve patient outcomes but also encourage manufacturers to invest in Research and Development to meet the growing demand. ## **US Gestational Diabetes Market Segment Insights** ### **Gestational Diabetes Market Diagnosis Type Insights** The US Gestational Diabetes Market encompasses various diagnosis types that play a critical role in the identification and management of gestational diabetes among pregnant women. Among these, the Oral Glucose Tolerance Test (OGTT) stands out as a standard method due to its ability to provide a comprehensive assessment of insulin response and glucose metabolism. This test typically requires patients to fast beforehand and then undergo a series of blood draws after consuming a sugary drink, making it an effective tool for diagnosing gestational diabetes. The Fasting Blood Sugar Test remains popular for its simplicity and convenience, as it measures blood sugar levels first thing in the morning, helping to identify abnormal glucose levels early in the pregnancy. Meanwhile, the Random Blood Sugar Test offers a quick diagnostic option that can be performed at any time, assessing glucose levels in real-time regardless of recent food intake. This flexibility can be particularly beneficial in settings where time is crucial. Lastly, the Hemoglobin A1c Test is increasingly recognized for its ability to provide an overview of average blood sugar levels over the past two to three months, although it is less commonly used in pregnancy due to specific guidelines. Overall, the US Gestational Diabetes Market segmentation by diagnosis type reflects the diverse approaches in the management of this condition, with each method having its own unique advantages and relevance in ensuring the health of both mothers and their babies. The specific emphasis on accurate diagnosis is essential, given that appropriate interventions can significantly reduce the risks of complications related to gestational diabetes. The choice of diagnostic method often depends on factors such as availability, patient preference, and clinical guidelines, influencing overall market dynamics and driving advancements in technology and patient management strategies within the industry. As healthcare providers continue to learn more about gestational diabetes, improvements in these diagnostic techniques are expected to evolve, contributing to better patient outcomes. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Gestational Diabetes Market Treatment Type Insights** The Treatment Type segment of the US Gestational Diabetes Market focuses on various methods employed to manage the condition effectively. Dietary Changes play a crucial role, as proper nutrition helps control blood sugar levels, promoting better outcomes for both mothers and infants. Insulin Therapy is significant for those who cannot manage their glucose levels with diet alone; it provides a direct method for controlling blood sugar. Oral Medications are also utilized, though their application can be limited during pregnancy; nonetheless, they represent an important option for specific patient needs. Physical Activity is vital, as structured exercise improves insulin sensitivity and contributes to overall well-being during pregnancy. The interplay between these treatment types highlights the multifaceted approach required to address gestational diabetes, emphasizing the necessity for personalized care plans. Trends suggest that both healthcare providers and patients are increasingly recognizing the significance of holistic treatment strategies, promoting the importance of lifestyle modifications alongside pharmacological interventions. With rising awareness of gestational diabetes implications, growth in this segment is expected, driven by both emerging research and an expanding recognition of maternal health's importance in the US healthcare industry. ### **Gestational Diabetes Market Risk Factor Insights** The US Gestational Diabetes Market is significantly influenced by various risk factors, which play a crucial role in understanding the evolving dynamics of the market. Among these, obesity is a prominent factor, as it has consistently linked to higher chances of developing gestational diabetes, making it an essential focus area for healthcare professionals and policy makers. Family history represents another significant risk factor; having close relatives with diabetes increases susceptibility, highlighting the need for targeted awareness campaigns aimed at at-risk populations. Age also stands as an important consideration, with older pregnant women facing elevated risks. Previous gestational diabetes is a critical aspect too, as women with a history of the condition have a much higher likelihood of experiencing it again in future pregnancies. The interplay of these risk factors not only affects individual health outcomes but also informs public health strategies and clinical practices aimed at managing and reducing the incidence of gestational diabetes. Understanding these risk factors helps in the development of preventive measures and aligns with the broader goals of enhancing maternal and fetal health in the US. ### **Gestational Diabetes Market Patient Age Insights** The US Gestational Diabetes Market showcases significant segmentation based on Patient Age, which plays a crucial role in understanding the demographics affected by this condition. Among the distinct age groups, Teenagers represent a growing prevalence, often influenced by lifestyle factors and rising obesity rates. This subset is crucial as early intervention can significantly impact their long-term health outcomes. Adults, particularly in the 25-35 age range, represent the majority holding within the market due to increased pregnancies among this demographic, driving awareness and screening practices for gestational diabetes. The Elderly population, while not the primary focus, still necessitates attention as delayed pregnancies become more common; their health complications could exacerbate gestational diabetes conditions. The market growth hinges on these dynamics, with targeted awareness campaigns and healthcare initiatives necessary to address the age-related risks associated with gestational diabetes. Additionally, there are opportunities emerging with advancements in technology and personalized healthcare that cater specifically to the unique needs of each age group, ensuring better management and outcomes in the US Gestational Diabetes Market. ## **US Gestational Diabetes Market Key Players and Competitive Insights** The US Gestational Diabetes Market has been experiencing significant growth, driven by a rising awareness of maternal health and the increasing prevalence of gestational diabetes among pregnant women. Various factors, including lifestyle changes, genetic predispositions, and an expanding aging population, have contributed to the rising incidence of this condition, prompting the demand for effective monitoring and treatment solutions. Competitive dynamics within this market reflect the presence of notable players who are continuously engaged in enhancing their product portfolios, improving patient care, and strategically collaborating to gain market share. Companies are focusing on innovations and technological advancements to streamline diabetes management and make diagnostic processes more efficient. The competitive landscape is characterized by the presence of established brands alongside emerging players, all vying to provide comprehensive solutions tailored to the specific needs of women experiencing gestational diabetes. ### **Key Companies in the US Gestational Diabetes Market Include** ### **US Gestational Diabetes Market Industry Developments** The US Gestational Diabetes Market has seen significant developments recently, particularly in the context of rising awareness and advancements in technology. Companies such as Abbott Laboratories and Roche Holding are increasingly focusing on the enhancement of diabetes management solutions, with a push toward digital health tools and continuous glucose monitors. In terms of market dynamics, the valuation of the market is experiencing growth due to the increasing prevalence of gestational diabetes and the introduction of new diagnostic tools. Notably, Quidel Corporation and Medtronic have made strides in expanding their product lines to address this growing need. In recent months, there have been reports of mergers and acquisitions affecting key players; for instance, Eli Lilly and Company’s acquisition of a small diabetes-focused firm was acknowledged in July 2023, reflecting a focused strategy on addressing gestational diabetes. Another significant move was made by Johnson and Johnson, which launched new clinical guidelines in February 2023 to improve management protocols. The collaboration between Dexcom and Ascensia Diabetes Care on integrated devices aims to streamline patient care, highlighting the industry's commitment to innovation and patient-centric solutions in the US market. ## **US Gestational Diabetes Market Segmentation Insights** ### **Gestational Diabetes Market Diagnosis Type Outlook** ### **Gestational Diabetes Market Treatment Type Outlook** ### **Gestational Diabetes Market Risk Factor Outlook** ### **Gestational Diabetes Market Patient Age Outlook** ## Market Drivers ### Rising Healthcare Expenditure The increasing healthcare expenditure in the US is another significant driver of the gestational diabetes market. As healthcare costs continue to rise, there is a growing emphasis on preventive care and management of chronic conditions, including gestational diabetes. The US spends over $3.5 trillion annually on healthcare, with a substantial portion allocated to maternal and child health services. This financial commitment is likely to enhance access to screening, treatment, and educational resources for women diagnosed with gestational diabetes. Consequently, the gestational diabetes market is poised for growth as healthcare providers invest in comprehensive care models that address the needs of pregnant women, ultimately improving health outcomes. ### Advancements in Treatment Options The gestational diabetes market is experiencing growth due to advancements in treatment options available for managing the condition. Innovations in insulin delivery systems, such as smart insulin pens and continuous glucose monitoring devices, are enhancing the management of gestational diabetes. These technologies allow for more precise monitoring of blood glucose levels, which is essential for both maternal and fetal health. Furthermore, the development of new dietary management programs and educational resources is empowering women to take control of their health during pregnancy. As these treatment options become more accessible, the gestational diabetes market is expected to expand, driven by the demand for effective and user-friendly solutions that cater to the needs of expectant mothers. ### Government Initiatives and Support Programs Government initiatives aimed at improving maternal health and reducing the incidence of gestational diabetes play a significant role in shaping the gestational diabetes market. Programs that promote awareness, screening, and education about gestational diabetes are being implemented at both state and federal levels. For instance, the Centers for Disease Control and Prevention (CDC) has launched campaigns to educate healthcare providers and expectant mothers about the risks associated with gestational diabetes. These initiatives not only enhance awareness but also encourage early screening and intervention, which is crucial for managing the condition effectively. As a result, the gestational diabetes market is likely to benefit from increased funding and resources allocated to maternal health programs, fostering a supportive environment for affected women. ### Increasing Prevalence of Gestational Diabetes The rising incidence of gestational diabetes among pregnant women in the US is a critical driver for the gestational diabetes market. Recent data indicates that approximately 6-9% of pregnancies in the US are affected by this condition, which translates to around 200,000 cases annually. This increasing prevalence is attributed to various factors, including rising obesity rates and lifestyle changes. As more women are diagnosed, the demand for effective management solutions, including glucose monitoring devices and dietary management programs, is likely to grow. Consequently, healthcare providers are focusing on early detection and intervention strategies, which further propels the gestational diabetes market. The need for comprehensive care and support for affected women is becoming increasingly recognized, leading to a more robust market landscape. ### Growing Demand for Personalized Healthcare Solutions The trend towards personalized healthcare solutions is significantly influencing the gestational diabetes market. As patients increasingly seek tailored treatment plans that consider their unique health profiles, healthcare providers are adapting their approaches to meet these demands. This shift is particularly relevant in the context of gestational diabetes, where individualized management strategies can lead to better health outcomes for both mothers and infants. The integration of data analytics and patient feedback into treatment plans is becoming more common, allowing for adjustments based on real-time health metrics. As personalized healthcare continues to gain traction, the gestational diabetes market is likely to expand, driven by the need for customized solutions that enhance patient engagement and satisfaction. ## Future Outlook The [Gestational Diabetes Market](https://www.marketresearchfuture.com/reports/gestational-diabetes-market-4591) is projected to grow at a 6.25% CAGR from 2025 to 2035, driven by rising prevalence and advancements in monitoring technologies. **New opportunities:** - Development of telehealth platforms for remote patient monitoring. Investment in AI-driven predictive analytics for risk assessment. Expansion of personalized nutrition programs targeting expectant mothers. By 2035, the market is expected to achieve substantial growth, driven by innovative solutions and increased awareness. ## Segment Insights ### By Diagnosis Type: Oral Glucose Tolerance Test (Largest) vs. Hemoglobin A1c Test (Fastest-Growing) In the US gestational diabetes market, the Oral Glucose Tolerance Test (OGTT) holds the largest market share among diagnosis types, driven by its widespread acceptance and established guidelines recommending it as the standard screening method for gestational diabetes. This test's reliability in diagnosing glucose metabolism issues contributes significantly to its dominant position in the market. Conversely, the Fasting Blood Sugar Test and Random Blood Sugar Test are also utilized but represent smaller shares of the market due to variations in clinical preferences and patient-specific factors. The growth trends within this segment are largely influenced by increased awareness and screening of gestational diabetes among pregnant women. Additionally, the Hemoglobin A1c Test is emerging as the fastest-growing option, thanks to advancements in technology that enhance its accuracy and ease of monitoring. Healthcare professionals are increasingly adopting this test due to its ability to provide a comprehensive overview of glucose control over time, catering to a more proactive approach in managing gestational diabetes. The rise in prevalence of obesity and related risk factors also fuels demand for effective diagnosis methods. Oral Glucose Tolerance Test (Dominant) vs. Hemoglobin A1c Test (Emerging) The Oral Glucose Tolerance Test (OGTT) is characterized by its comprehensive assessment of glucose levels post-glucose intake, making it the preferred choice in diagnosing gestational diabetes. Its dominance is underscored by clinical guidelines recommending it for routine screening, ensuring that a significant portion of pregnant women undergo this test. In contrast, the Hemoglobin A1c Test, though emerging, is rapidly gaining traction due to its ability to reflect long-term glucose control, enabling better patient management strategies. This adoption is partially driven by technological improvements that allow for more rapid and user-friendly testing processes, positioning it as a favorable option for women and healthcare providers seeking efficient monitoring solutions amid rising health concerns related to gestational diabetes. ### By Treatment Type: Dietary Changes (Largest) vs. Insulin Therapy (Fastest-Growing) In the US gestational diabetes market, dietary changes hold the largest market share, representing a fundamental approach to managing the condition. This treatment type involves a significant shift in patients' eating habits, focusing on nutritional balance and controlled carbohydrate intake to stabilize blood glucose levels. Insulin therapy, while currently smaller in market share, is rapidly growing as more healthcare providers recognize its essential role for patients who cannot achieve optimal glycemic control through diet alone. The growth in this segment is primarily driven by increasing awareness of gestational diabetes and heightened medical guidelines for treatment. Insulin therapy has been recognized for its effectiveness in providing faster results, leading to its rising adoption among healthcare providers and patients alike. Additionally, advancements in insulin delivery methods are contributing to the expansion of this treatment option, making it more user-friendly and less intimidating for mothers-to-be. Dietary Changes (Dominant) vs. Oral Medications (Emerging) Dietary changes play a dominant role in the management of gestational diabetes, emphasizing the importance of tailored nutritional plans. This approach is characterized by its accessibility and non-invasive nature, allowing patients to make lifestyle adjustments without the immediate need for pharmaceuticals. In contrast, oral medications have emerged as a significant alternative, increasingly utilized in cases where dietary management alone is insufficient. Oral medications provide a convenient option for those who face challenges adhering to dietary changes. As awareness and understanding of gestational diabetes grow, both dietary changes and oral medications are expected to coexist, providing comprehensive options for effective management. ### By Risk Factor: Obesity (Largest) vs. Age (Fastest-Growing) Among the various risk factors associated with gestational diabetes in the US gestational diabetes market, obesity stands out as the largest contributor, significantly influencing the prevalence rates. This segment is characterized by a growing number of individuals classified as overweight, which correlates with increased insulin resistance and metabolic disturbances, leading to higher incidences of gestational diabetes. Additionally, family history and previous gestational diabetes are critical factors that also contribute to market dynamics, but obesity remains the most prominent. In terms of growth trends, the age factor is emerging as the fastest-growing risk factor in the US gestational diabetes market. As societal trends shift towards delayed childbearing among women, the correlation between advanced maternal age and gestational diabetes becomes increasingly evident. This trend is driven by lifestyle changes, including increased rates of obesity and lack of physical activity, further exacerbating the risks associated with older maternal age. Such findings underscore the need for targeted prevention and intervention strategies aimed at these demographic shifts. Obesity: Dominant vs. Age: Emerging Obesity is recognized as the dominant risk factor in the US gestational diabetes market, with a strong correlation to elevated blood sugar levels during pregnancy. This condition is associated with various metabolic complications that lead to gestational diabetes, making it a primary concern for healthcare providers. Conversely, the age factor is emerging rapidly, characterized by a rising prevalence of gestational diabetes among older mothers. As women increasingly choose to start families later in life, healthcare experts are observing a notable increase in cases attributed to age-related risks. Both factors are pivotal in shaping clinical practices and public health strategies aimed at mitigating the risks of gestational diabetes. ### By Patient Age: Adults (Largest) vs. Teenagers (Fastest-Growing) In the US gestational diabetes market, the patient age segment is predominantly represented by adults, who account for a significant share due to higher incidences among this demographic. Teenagers, although smaller in volume, are increasingly being recognized as a vital group for screening and intervention, leading to a notable shift in market focus towards them. The elderly segment remains relevant but contributes less to the overall share. Growth trends indicate that awareness and education about gestational diabetes are rising, particularly among teenagers, encouraging early diagnosis and management. Consequently, the adult segment continues to dominate, while efforts to support the teenage population are enhancing their market presence as the fastest-growing group, driven by increased healthcare initiatives aimed at improving maternal and fetal health outcomes. Adults: Dominant vs. Teenagers: Emerging The adult segment is the dominant force in the US gestational diabetes market, primarily due to higher prevalence rates as women in this age group are more likely to experience this condition. This demographic benefits from a wealth of resources available for management and treatment while being targeted through various healthcare programs. On the other hand, the teenage segment is emerging as an important focus, driven by concerns over rising obesity rates and related health issues. As healthcare providers emphasize early intervention, teenagers are becoming increasingly monitored, resulting in greater market attention and tailored strategies to accommodate their unique needs and ensure healthier pregnancies. ## Competitive Benchmarking The gestational diabetes market in the US is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as Abbott Laboratories (US), Roche Holding AG (CH), and Novo Nordisk (DK) are actively engaged in enhancing their product offerings and expanding their market presence. Abbott Laboratories (US) has positioned itself as a leader in continuous glucose monitoring systems, which are crucial for managing gestational diabetes. Meanwhile, Roche Holding AG (CH) emphasizes its commitment to digital health solutions, integrating advanced data analytics into its diabetes management tools. Novo Nordisk (DK) focuses on developing innovative insulin therapies tailored for pregnant women, thereby addressing a critical need in the market. Collectively, these strategies indicate a shift towards more personalized and technology-driven approaches in managing gestational diabetes.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure of the market appears moderately fragmented, with several players vying for market share. However, the influence of major companies is substantial, as they leverage their resources and expertise to shape market dynamics. This competitive interplay fosters an environment where innovation and strategic collaborations are paramount. In October Abbott Laboratories (US) announced the launch of a new version of its continuous glucose monitoring system, designed specifically for pregnant women. This strategic move is significant as it not only reinforces Abbott's commitment to addressing the unique challenges faced by this demographic but also positions the company to capture a larger share of the growing gestational diabetes market. The introduction of tailored solutions is likely to enhance patient adherence and improve health outcomes. In September Roche Holding AG (CH) entered into a partnership with a leading telehealth provider to enhance remote monitoring capabilities for gestational diabetes patients. This collaboration is indicative of Roche's strategy to integrate digital health solutions into its product offerings, thereby facilitating better patient engagement and management. The partnership may also serve to expand Roche's reach in the telehealth space, aligning with current trends towards remote healthcare delivery. In August Novo Nordisk (DK) launched a new educational initiative aimed at healthcare providers to improve awareness and management of gestational diabetes. This initiative underscores Novo Nordisk's focus on education as a critical component of diabetes care. By equipping healthcare professionals with the necessary knowledge and tools, the company aims to enhance treatment outcomes and foster a more informed patient population. As of November the competitive trends in the gestational diabetes market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) into healthcare solutions. Strategic alliances are playing a crucial role in shaping the landscape, as companies collaborate to leverage each other's strengths. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on innovation, technology, and supply chain reliability. This shift may ultimately lead to improved patient outcomes and a more sustainable approach to managing gestational diabetes. ## Recent News & Developments The US Gestational Diabetes Market has seen significant developments recently, particularly in the context of rising awareness and advancements in technology. Companies such as Abbott Laboratories and Roche Holding are increasingly focusing on the enhancement of diabetes management solutions, with a push toward digital health tools and continuous glucose monitors. In terms of market dynamics, the valuation of the market is experiencing growth due to the increasing prevalence of gestational diabetes and the introduction of new diagnostic tools. Notably, Quidel Corporation and Medtronic have made strides in expanding their product lines to address this growing need. In recent months, there have been reports of mergers and acquisitions affecting key players; for instance, Eli Lilly and Company’s acquisition of a small diabetes-focused firm was acknowledged in July 2023, reflecting a focused strategy on addressing gestational diabetes. Another significant move was made by Johnson and Johnson, which launched new clinical guidelines in February 2023 to improve management protocols. The collaboration between Dexcom and Ascensia Diabetes Care on integrated devices aims to streamline patient care, highlighting the industry's commitment to innovation and patient-centric solutions in the US market. ## Report Scope | MARKET SIZE 2024 | 417.9(USD Million) | | --- | --- | | MARKET SIZE 2025 | 444.02(USD Million) | | MARKET SIZE 2035 | 814.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.25% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Abbott Laboratories (US), Roche Holding AG (CH), Boehringer Ingelheim (DE), Sanofi (FR), Novo Nordisk (DK), Merck & Co. (US), Johnson & Johnson (US), Bayer AG (DE) | | Segments Covered | Diagnosis Type, Treatment Type, Risk Factor, Patient Age | | Key Market Opportunities | Integration of digital health solutions enhances monitoring and management in the gestational diabetes market. | | Key Market Dynamics | Rising prevalence of gestational diabetes drives demand for innovative monitoring technologies and personalized treatment solutions. | | Countries Covered | US | ## Frequently Asked Questions **Q: What is the current valuation of the US gestational diabetes market?** A: The market valuation was $417.9 Million in 2024. **Q: What is the projected market size for the US gestational diabetes market by 2035?** A: The projected valuation for 2035 is $814.0 Million. **Q: What is the expected CAGR for the US gestational diabetes market during the forecast period 2025 - 2035?** A: The expected CAGR is 6.25% during the forecast period. **Q: Which companies are the key players in the US gestational diabetes market?** A: Key players include Abbott Laboratories, Roche Holding AG, Boehringer Ingelheim, Sanofi, Novo Nordisk, Merck & Co., Johnson & Johnson, and Bayer AG. **Q: What are the main diagnosis types in the US gestational diabetes market?** A: Main diagnosis types include Oral Glucose Tolerance Test, Fasting Blood Sugar Test, Random Blood Sugar Test, and Hemoglobin A1c Test. **Q: What is the valuation range for the Oral Glucose Tolerance Test segment?** A: The valuation range for the Oral Glucose Tolerance Test segment is $100.0 - $200.0 Million. **Q: What treatment types are prevalent in the US gestational diabetes market?** A: Prevalent treatment types include Dietary Changes, Insulin Therapy, Oral Medications, and Physical Activity. **Q: What is the valuation range for Insulin Therapy in the treatment segment?** A: The valuation range for Insulin Therapy is $125.7 - $250.0 Million. **Q: What are the primary risk factors associated with gestational diabetes?** A: Primary risk factors include Obesity, Family History, Age, and Previous Gestational Diabetes. **Q: What is the valuation range for the patient age segment in the US gestational diabetes market?** A: The valuation range for the patient age segment includes Teenagers at $25.0 - $50.0 Million, Adults at $300.0 - $600.0 Million, and Elderly at $92.9 - $164.0 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-gestational-diabetes-market-19944*